Treatment for macular degeneration. Vial of the monoclonal antibody ranibizumab, marketed under the tradename Lucentis, that is used to treat age-rela

---

Treatment for macular degeneration. Vial of the monoclonal antibody ranibizumab, marketed under the tradename Lucentis, that is used to treat age-related macular degeneration (AMD). Lucentis is injected into the eye (intravitreal use) to treat the vascular damage to the retina seen in AMD. Lucentis prevents abnormal retinal blood vessels forming, and dries up leaking blood vessels. Lucentis is marketed by the multinational pharmaceutical company Novartis.

---

Size: 3661px × 4890px
Photo credit: © DR P. MARAZZI/SCIENCE PHOTO LIBRARY / Alamy / Afripics
License: Licensed
Model Released: No

Keywords: -life, age-related, amd, antibody, blood, clinic, condition, container, cut, cut-, cut-outs, cutout, cutouts, degeneration, disorder, drug, eye, hospital, intravitreal, label, labelled, life, lucentis, macular, medical, medicine, novartis, ocular, operating, operation, ophthalmic, ophthalmology, outs, people, person, phial, ranibizumab, retina, retinal, room, studio, treatment, vascular, vessels, vial